pdufa.bio
HomePDUFA Calendar › GSK

GSK plc American Depositary Shares (Each representing two) (GSK) FDA catalysts & readout calendar

Updated ·next FDA decision on the calendar
GSK plc · 1 upcoming · 10 past FDA decisions

Upcoming FDA catalysts

GSK · Oct 26, 2026Bepirovirsen - (B-Well): Chronic hepatitis B

FDA decision history (10)

Jun 17, 2026✓ ApprovedFDA decisionMar 19, 2026✓ ApprovedFDA decisionMar 13, 2026✓ ApprovedFDA decisionDec 11, 2025✓ ApprovedFDA decisionOct 23, 2025✓ ApprovedFDA decisionJul 17, 2025✓ ApprovedFDA decisionJun 24, 2025✓ ApprovedFDA decisionMay 22, 2025✓ ApprovedFDA decisionMar 25, 2025✓ ApprovedFDA decisionFeb 17, 2025unverifiedFDA decision
Full PDUFA calendar →All FDA decisions →Phase readouts →
See the full 2026 PDUFA calendar →

This page aggregates GSK's FDA catalysts from pdufa.bio's own calendar and decision archive. Each item links to its source page. Facts and dates only; verify against primary FDA / SEC / company filings.

GSK run-up, measured

Computed from this stock's own daily closing prices, on the same T-120 basis as the run-up study: the baseline is the close 120 trading sessions before the eve of the decision. These are measurements of what already happened, not predictions.

GSK's past FDA decisions (n=38)
DecisionOutcomeT-120 to eveT-120 to peak
2026-06-17APPROVAL+7.5%+25.9%
2026-03-19APPROVAL+29.6%+52.3%
2026-03-13APPROVAL+34.7%+51.8%
2025-12-11APPROVAL+27.2%+28.6%
2025-10-23APPROVAL+14.2%+17.4%
2025-07-17APPROVAL+14.5%+27.1%
2025-06-24APPROVAL+12.1%+24.5%
2025-05-22APPROVAL+12.9%+18.3%
2025-03-25APPROVAL-5.3%+0.4%
2025-02-17APPROVAL-13.8%+5.5%
2024-11-13CRL-22.4%+0.0%
2024-08-01APPROVAL-7.7%+8.9%
Showing the 12 most recent of 38.
Median across these 38 decisions: +6.3% from T-120 to the eve, +10.4% to the peak. A median over 38 events describes this stock's past only. It is not a forecast, and the cohort figures on the run-up study are the larger statistical base.

Common questions

When is the next FDA decision or readout for GSK plc American Depositary Shares (GSK)?

October 26, 2026. The next catalyst for GSK plc American Depositary Shares is Bepirovirsen - (B-Well) (PDUFA). That date is a confirmed date. Dates are taken from FDA notices, company filings or ClinicalTrials.gov, and we do not publish a specific day when the source only gives a month or a quarter.

Has GSK plc American Depositary Shares (GSK) had an FDA decision before?

Yes, 10 in our archive: 10 approval(s) and 0 Complete Response Letter(s). The most recent was on June 17, 2026 and was an approval. Each one has its own page with the source document and the share-price reaction we measured.

How has GSK stock moved into its FDA decisions?

Measured from this company's own daily closing prices: Median across these 38 decisions: +6.3% from T-120 to the eve, +10.4% to the peak. These are historical measurements of what already happened, not forecasts, and we publish no price targets or probability of approval.

Where does this GSK data come from?

FDA publications, company filings with the SEC, company press releases and ClinicalTrials.gov, with share prices measured from daily closing data. Every date and outcome links the document it came from. Where an outcome was inferred from the price reaction rather than read from a filing, the page says so on its face.